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OBJECTIVES This study was designed to investigate the use of magnetic resonance (MR) functional and
perfusion imaging to evaluate laser myocardial revascularization (LMR).
BACKGROUND Most clinical studies of LMR have shown improvements in angina class and exercise capacity,
with minimal or absent improvements in myocardial perfusion and function.
METHODS Fifteen patients who underwent percutaneous Biosense-guided holmium:yttrium aluminum
garnet LMR to areas of viable but ischemic myocardium were followed clinically and
underwent functional and perfusion MRI at baseline, 30 days and 6 months.
RESULTS The mean age was 64 11 years; four patients were women. The ejection fraction was 47.4
14.0%. Angina class at baseline was 3.4  0.6 and improved to 2.5  1.4 at six months (p 
0.054). Exercise time at baseline was 298  97 s and increased to 350  95 s at 30 days and
365  79 s at six months, p  0.04. There were no significant changes in nuclear perfusion
scans. Although MR determined that resting radial motion and thickening of the target wall
were significantly less than normal at baseline (p 0.001), they improved significantly during
follow-up (wall thickening: baseline, 30.6  11.7%; day 30, 41.2  13.3% and day 180,
44.2  11.9%, p  0.01). The size of the underperfused myocardial area was 14.5  5.4% at
baseline and was reduced to 6.3  2.8% at 30 days and 7.7  3.7% at 6 months (p  0.001).
CONCLUSIONS This small phase I, open-label, uncontrolled study of MR functional and perfusion imaging
in patients undergoing Biosense-guided LMR suggests a beneficial effect of this treatment
strategy on myocardial function and perfusion. The efficacy of Biosense-guided LMR is being
evaluated in a large phase II, randomized, blinded placebo-controlled trial with an MRI
substudy (DIRECT). (J Am Coll Cardiol 2002;39:1–8) © 2002 by the American College
of Cardiology
With the recent approval of the CO2 (PLC, Franklin,
Massachusetts) and holmium:yttrium aluminum garnet
(Ho:YAG; Eclipse, Sunnyvale, California) surgical lasers
(1), laser myocardial revascularization (LMR) has become a
therapeutic option for patients with medically refractory
angina who are considered to be suboptimal candidates for
standard catheter-based or surgical revascularization strate-
gies (1–5). The Ho:YAG laser’s infrared wavelength also
allows transmission through optical fibers, making percuta-
neous catheter-based LMR possible with any of several laser
systems under active study (Cardiogenesis, Eclipse and
Biosense) (6–8). The proposed mechanisms of LMR ben-
efits include: 1) myocardial perfusion from the left ventricle
(LV) through patent laser channels, a hypothesis that is
becoming less likely with evidence of early channel occlu-
sion (9–12); 2) new blood vessel growth (myocardial angio-
genesis) resulting from release of growth factors and inflam-
matory mediators (13–17); 3) myocardial denervation
leading to reduced symptoms without improved perfusion
(18); 4) myocardial fibrosis resulting in a tethering action
that improves myocardial function and promotes favorable
remodeling; or 5) placebo effect in a highly motivated
patient population undergoing a high-tech procedure.
The question is still whether LMR is indeed a form of
revascularization strategy, or whether it is only a means of
providing symptomatic relief without increasing myocardial
perfusion (and without consequent benefits in myocardial
function, survival or myocardial infarction, or the need for
repeat revascularization, or LV function) (2,12,17,19–21).
In fact, most clinical studies of LMR have shown a
discrepancy between the significant improvements in angina
class and exercise capacity (2,12,14,19,20,22,23) and the
minimal or absent improvements in myocardial perfusion
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and function (24–28). These beneficial effects on perfusion
or function are either absent or below the detection limits of
currently available imaging modalities (e.g., because of the
poor spatial resolution of nuclear perfusion scans and the
lack of reproducibility and frequent poor imaging windows
of transthoracic echocardiography) (1,2,11,19,21–23,29).
Magnetic resonance imaging (MRI) is an alternative
imaging modality that allows serial noninvasive assessment
of global and regional myocardial function, the extent of
myocardial ischemia using myocardial blood/contrast arrival
imaging (30–34) and the extent of myocardial collateraliza-
tion (35,36). It has been used to investigate the angiogenic
potential of several growth factors (30,37–39) but has not
yet been used to investigate the “revascularization” effect of
LMR. We thus report the 30-day and 6-month results of a
pilot MRI evaluation, performed in the recently completed
phase I Biosense-guided LMR study, as a prelude to its use
in the randomized blinded placebo-controlled phase II
Direct Myocardial Revascularization In Regeneration of
Endomyocardial Channels Trial (DIRECT) LMR study.
METHODS
Patient selection. The study sample consisted of patients
undergoing Biosense electromechanical triangulation guid-
ance system (NOGA)-guided LMR at Boston’s Beth Israel
Deaconess Medical Center. To be eligible, patients needed
to have: 1) an area of myocardium supplied by a major
coronary artery with advanced disease not amenable to
bypass grafting or percutaneous intervention; or 2) a corre-
sponding area of inducible ischemia (fully or partially
reversible defect on a nuclear perfusion scan). They could
not have: 1) unstable angina, recent myocardial infarction or
recent (three months) coronary angioplasty; 2) ejection
fraction30%; 3) aortic stenosis or sclerosis, or a prosthetic
valve; or 4) severe peripheral vascular disease. Additional
MRI-specific exclusion criteria included cardiac pacemak-
ers, frequent atrial or ventricular arrhythmias, cerebral metal
implants and severe claustrophobia. The study was approved
by the Committee for Clinical Investigation of the Beth
Israel Deaconess Medical Center. Patients were enrolled
between March 1998 and September 1998.
LMR. Patients enrolled in the study underwent LMR
using Biosense guidance. This NOGA system allows accu-
rate on-line localization of the catheter tip within the LV,
map (40–42) relative to three location pads that are
positioned under the subject’s back and emit an ultralow
(106-105Tesla) magnetic field. The intensity of the three
magnetic fields is detected by miniature antennae within the
tip of a deflectable catheter, providing precise spatial local-
ization after triangulation within a Silicon Graphics work-
station. As the catheter is placed sequentially against the LV
endocardial surface at a series of points, the local unipolar
electrogram and tip motion during the cardiac cycle are
recorded. This allows calculation of unipolar voltage and
local wall shortening (percent change in the average distance
between a point and its neighbors from end-diastole to
end-systole) at each such point. A three-dimensional map of
each parameter can be displayed and rotated freely in space
to inspect all LV walls. Areas of reduced local unipolar
voltage and reduced local shortening indicate scar; areas of
preserved local unipolar voltage and reduced local shorten-
ing indicate severe resting ischemia (40–42). Following
diagnostic mapping, a second catheter with the same tip
sensor and a laser fiber is used to administer Ho:YAG laser
pulses (2 J) to the ischemic areas indicated on the baseline
NOGA map. Fifteen to 25 laser channels are performed in
each ischemic area, up to a maximum of two zones (Fig. 1).
Follow-up. Patients were followed for six months follow-
ing the index procedure. Transthoracic echocardiograms
were performed at baseline, 24 h following the index
procedure and at one month of follow-up. Patients were
followed for six months for death, myocardial infarction,
need for repeat revascularization and angina class (43).
Exercise treadmill testing and rest thallium-adenosine
sestaMIBI nuclear perfusion scans were performed at base-
line, 30 days and 6 months following LMR. Nuclear scans
were subjected to core laboratory analysis using a semiquan-
titative segmental analysis and an automated quantitative
analysis. In addition, left ventriculography, coronary an-
giography and Biosense NOGA mapping were performed
at baseline to guide therapy and then at six months of
follow-up. Clinical follow-up of at least six months was
available on all patients.
MRI. Magnetic resonance imaging was performed at base-
line, and at 30 days and 6 months. MRI was performed in
the body coil of a 1.5 Tesla whole-body Siemens Vision
system. Functional imaging was performed during breath-
hold using shared-center FLASH cine imaging in each of
the three mutually perpendicular views comprising biplane
long axis and a stack of short-axis views, with short axis
imaged from base to apex in contiguous sections 0.5 cm
thick, collected over approximately 12 heartbeats to measure
regional wall systolic thickening and motion. Magnetic
resonance blood arrival imaging was assessed, as previously
described (30,37). A series of four inversion recovery images
were obtained with the inversion time (TI) adjusted to
minimize signal intensity from myocardium. Using the best
TI for nulling myocardial signal, a series of concurrent
parallel images were acquired in diastole during breath-
hold, at baseline and after the bolus injection of contrast
media (0.05 mmol/kg gadodiamide) (30,34,44). For perfu-
sion imaging, three slices were obtained in each patient.
Abbreviations and Acronyms
ANOVA  analysis of variance
CCS  Canadian Cardiovascular Society
Ho:YAG  holmium:yttrium aluminum garnet
LMR  laser myocardial revascularization
MRI  magnetic resonance imaging
TI  inversion time
TMR  transmyocardial revascularization
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Measurement of the timing of half-maximum signal arriv-
ing in the different parts of the myocardium demonstrated
the existence of several distinct regions including normal
myocardium and areas exhibiting delayed contrast arrival
(underperfused zones). For each scan, a space-time map
demonstrating distribution of contrast signal density over
the LV wall as a function of time was created. The extent of
the territory demonstrating delayed arrival of contrast,
defined as 1 s delay of contrast density reaching its 50%
maximum value reflecting the most severely hypoperfused
part of the myocardium, was then calculated and expressed
as percent of the total LV myocardial area (30). If more than
one area was treated, the extents of delayed contrast arrival
zone in both areas were measured. Magnetic resonance
analysis was performed in a semiautomated fashion by a core
lab blinded to study sequence.
Statistical methods. Data are expressed as mean  stan-
dard deviation. The changes in the exercise treadmill test
time and MR measurements were evaluated using two-way
repeated-measures analysis of variance (ANOVA). In addi-
tion, measurements at 30 days and 6 months were compared
to baseline using paired Student t test. All reported p-values
were two-tailed, and a p-value 0.05 was considered
statistically significant.
RESULTS
Patient population. Nineteen patients met all eligibility
criteria for the Biosense Phase I LMR study and were
treated at Boston’s Beth Israel Deaconess Medical Center.
Of these patients, 15 patients underwent MRI exclusion
(pacemaker in 1 patient, unavailability of the magnet in 2
patients and claustrophobia in the fourth patient) and are
the focus of this study. The baseline characteristics are
presented in Table 1. The mean age was 64  11 years
(range 38 to 77 years) with four women. Seven patients
(46.7%) had diabetes mellitus, 13 patients (86.7%) had
hypertension and 14 patients (93.3%) had prior coronary
artery bypass grafts. The mean ejection fraction (evaluated
by left ventriculography) was 47.4  14.0% (range 30% to
73%). Fourteen patients (93.3%) had Canadian Cardiovas-
cular Society (CCS) Class III or IV angina.
Figure 1. Left anterior oblique cranial Biosense NOGA unipolar (left) and linear local shortening map (right) shows reduced anterolateral wall linear local
shortening in red (regional function) with preserved unipolar voltage indicating viable but underperfused myocardium. Twenty-five laser channels were
created using the Biosense Ho:YAG laser system (brown dots) in the “ischemic” zone (red) of the anterolateral wall.
Table 1. Baseline Clinical Characteristics
Patients (n  15)
Age (range) 64.1  11 (42–77)
Men/women 11/4
Diabetes mellitus 7 (46.7%)
Hypertension 13 (86.7%)
History of elevated cholesterol* 14 (93.3%)
Prior CABG 14 (93.3%)
Current tobacco use 4 (26.7%)
Prior PTCA 8 (53.3%)
Prior CVA/TIA 2 (13.3%)
Prior myocardial infarction 9 (60%)
Canadian Cardiovascular Society
Class III 7 (46.7%)
Class IV 7 (46.7%)
Ejection fraction by left ventriculography (range) 47.4  14.0 (30–73)
*Serum cholesterol 200 mg/dl.
CABG  coronary artery bypass grafting; CVA/TIA  cerebrovascular accident/
transient ischemic attack; EF  ejection fraction; PTCA  percutaneous translumi-
nal coronary angioplasty; MR  magnetic resonance imaging.
3JACC Vol. 39, No. 1, 2002 Laham et al.
January 2, 2002:1–8 LMR Improves Regional Function and Myocardial Perfusion
Acute results and intermediate-term follow-up. After
NOGA mapping, the delineated target treatment area was
22  11% of the endocardial surface area as judged by the
maps. Biosense-guided LMR was performed with 32  9
laser channels (range 17 to 49 channels with a mean channel
density 1.1  0.6 channels/cm2 within the treatment zone,
Fig. 1). The procedure was successful in all patients and
there were no acute procedural complications (death, myo-
cardial infarction, emergent revascularization, LV perfora-
tion or stroke). At six months of follow-up there were no
deaths, Q-wave myocardial infarctions or repeat revascular-
izations. One patient had a non–Q-wave myocardial infarc-
tion at three months. The mean angina class (CCS) at
baseline was 3.4  0.6 and improved to 2.5  1.4 at six
months (p  0.054). The mean exercise time was 298 
97 s at baseline, 350  95 s (p  0.11) at 30 days, and
365  79 s (p  0.02), at 6 months (ANOVA, p  0.04).
There were no significant changes in nuclear perfusion scan
stress sum scores, redistribution score or rest sum scores as
assessed by core laboratory analysis.
MRI. LEFT VENTRICULAR FUNCTION ASSESSMENT. Mag-
netic resonance imaging was performed in all 15 patients at
baseline and was repeated at day 30 (n  13) and at six
months (n  15). Each scan assessed resting ejection
fraction, resting regional wall motion and thickening and
myocardial contrast arrival. Systolic radial motion and
thickening of the target area (treated area) and normal wall
(best function) were measured using a semiautomated quan-
tification algorithm of short-axis MR images (Fig. 2).
Overall LV function was 48.8  11.4% at baseline, similar
to the left ventriculography assessment (47.4  14.0%, p 
0.76). There was a trend towards slight improvement in LV
function at day 180 (day 30 ejection fraction 52.3  11.8%
and day 180 ejection fraction 56.1  12.7%), which did not
reach statistical significance (p  0.25).
Resting baseline thickening (45.3  11.5%) of the
normal wall did not change significantly throughout the
study, but there was a trend towards improvement of normal
wall systolic radial motion (from 22.8  9.4% to 25.8 
9.4% at 30 days, and 30.8  3.9% at 6 months, ANOVA
p  0.02, Fig. 3). Resting radial motion and thickening of
the target wall were significantly less than that of the normal
wall at baseline (p  0.001, Fig. 3), and improved signifi-
cantly at 30 days and 6 months. The improvements in target
wall thickening (baseline, 30.6  11.7%; day 30, 41.2 
13.3%, p  0.03; and day 180, 44.2  11.9%, p  0.003,
ANOVA p  0.01, Fig. 3, top), and target wall motion
(baseline, 16.3  9.2%; day 30, 21.8  9.5%, p  0.01; and
day 180, 25.3  7.3%, p  0.006, ANOVA p  0.02, Fig.
3, bottom) were both statistically significant at day 180.
MYOCARDIAL PERFUSION/CONTRAST ARRIVAL ASSESS-
MENT. Myocardial perfusion/contrast arrival was assessed
using MRI (Fig. 4). The mean size of the delayed contrast
arrival zone (underperfused area of the myocardium) was
14.5  5.4% of the LV at baseline. The size of the
myocardial area demonstrating delayed contrast arrival,
corresponding to the laser-treated group, was reduced sig-
nificantly (ANOVA p  0.0001) at day 30 (6.3  2.8%,
p  0.001) and day 180 (7.7  3.7%, p  0.001), as
compared to baseline. There was no correlation between the
density or number of laser channels used and the improve-
ment in regional wall function or extent of improvement in
myocardial hypoperfusion.
DISCUSSION
In this phase I trial of Biosense-guided LMR, the main
intent was to demonstrate the safety and feasibility of this
treatment strategy. In the small group of patients enrolled at
our single center, the treatment was safe and was associated
with improvement in both angina class and exercise capac-
ity. Although there was no demonstrable improvement in
nuclear perfusion scans, assessment of MR perfusion/
contrast arrival demonstrated a concomitant reduction of
the size of the underperfused area within the treated zones.
Magnetic resonance imaging also showed an improvement
in regional wall radial motion and systolic thickening of the
laser-treated myocardial regions, whose regional function
had been reduced at baseline. Assessment of MR perfusion/
contrast arrival demonstrated a concomitant reduction of
the size of the underperfused area within the treated zones.
This study is thus the first demonstration of specific
Figure 2. Functional imaging was performed during breath-hold using shared-center FLASH imaging producing 16 to 24 sequential image frames each
(cine MR), collected over approximately 12 heartbeats to measure regional wall systolic thickening and motion. The target wall(s) was interrogated (arrow)
using an automated algorithm and displayed as a function of time allowing the determination of target wall motion and thickening.
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improvement in function and “perfusion” of the laser treated
zones.
Although the small sample size, the absence of a control
group and the absence of a correlation with the number and
density of laser channels preclude any definitive conclusions
regarding efficacy, these findings of improved perfusion and
function in the treated segments would support a potential
revascularization mechanism for LMR. On the other hand,
the concomitant improvements in normal wall motion and
trend for overall improvement in LV ejection fraction may
suggest a role of improved cardiac conditioning, which
could be related to nonspecific “cardiac rehabilitation effect”
after relief of angina by any mechanism, including a placebo
effect. However, this could be attributed to favorable re-
modeling after LMR. Treatment-specific benefit can only
be demonstrated within a blinded placebo-controlled study
of LMR, as will be possible from the MRI substudy of the
300-patient DIRECT study.
It should also be pointed out that although cardiac MRI
is considered the “gold standard” for evaluation of LV
function (31,45), its application to clinical trials in coronary
disease to date is very limited (46). Similarly, despite recent
advances in magnetic resonance-based perfusion assessment
of the myocardium (30,44,47,48), there has been no sub-
stantial clinical experience with this imaging modality (49).
In prior animal studies, we have documented improvement
in magnetic resonance-assessed parameters of LV function
in the setting of angiogenic growth factor therapy
(30,38,50). In addition, the newly developed variation of
MR perfusion imaging that relies on generation of space-
time maps proved capable of detecting changes in coronary
perfusion in a pig ameroid model (30,38) and proved
capable of detecting improved regional myocardial perfusion
in patients (37).
Comparison to prior clinical trials of LMR. These data
shed important light on other recently reported (non-
blinded) trials of LMR. A phase II study of surgical
transmyocardial laser revascularization (TMR) versus med-
ical therapy enrolled 275 patients followed for one year (51).
Angina, exercise tolerance and quality-of-life scores were
significantly higher in the transmyocardial-revascularization
group than in the medical-therapy group, with no differ-
ences in myocardial perfusion between the two groups, as
assessed by nuclear imaging (51). A second study enrolled
182 patients and randomized them to continued medical
therapy versus surgical TMR (24). At 12 months, again
exercise tolerance, angina and quality of life assessment were
significantly improved in the TMR group as compared with
the medical treatment group, without improvement in
nuclear perfusion (24). A third randomized study of surgical
Figure 3. Resting normal (black bars) and target (white bars, treated) wall thickening (top) and radial wall motion (bottom) showed improvement in the
target wall function at 30 and 180 days. In addition, there was a significant improvement in normal wall motion at 180 days. *Statistical significance with
a p  0.05 by paired t test. ANOVA  analysis of variance.
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TMR versus medical therapy enrolled 192 patients and
showed improved angina, quality of life and myocardial
perfusion as assessed by nuclear perfusion imaging in the
TMR group as compared to medical therapy (52). A fourth
randomized study of TMR versus medical therapy enrolled
100 patients and showed improvement in angina and
exercise capacity without any significant change in nuclear
perfusion scans in the TMR group as compared to medically
treated patients. Thus, most clinical studies of LMR have
shown significant improvements in angina class and exercise
capacity (6,7,24,25,27,28,51–53), with most studies show-
ing no significant or consistent improvement in perfusion
and myocardial function (24–28). Therefore, these benefi-
cial effects are either not present or cannot be detected with
currently available imaging modalities. The poor spatial
resolution of nuclear perfusion scans and the lack of repro-
ducibility and frequent poor imaging windows of transtho-
racic echocardiography have been blamed for the lack of
demonstrable improvement in perfusion and function
(6,7,24,25,27,28,51–53).
In the current study, MR appears to be a promising novel
imaging modality that may circumvent these limitations. Its
application in our patient cohort suggested a beneficial effect
of LMR on both perfusion and function. This is particularly
important because demonstrating a true revascularization
effect (improved perfusion and function) will be crucial to
acceptance of this treatment strategy in patients with severe
ischemic heart disease, particularly absent objective evidence
of hard clinical benefit (enhanced survival, freedom from
cardiac adverse events).
Conclusions. This small phase I open-label study using
MRI in patients undergoing Biosense-guided LMR sug-
gests a beneficial effect of this treatment strategy on myo-
cardial perfusion and function. The efficacy and safety of
Biosense-guided LMR is currently being evaluated in a
large phase II, randomized, blinded placebo-controlled trial
with an MRI substudy (DIRECT).
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